Virology (HCV)

Selection Pressures During IFN Therapy Differ Among Patients

Published in Hepatitis Weekly, September 7th, 1998

Selection pressures evoked on hepatitis C virus genotype 1 quasispecies during interferon therapy appear to differ among patients, according to a report from the University of Washington.

The findings of researcher Stephen J. Polyak and colleagues could have significant clinical impact.

"The clinical importance of the current study is the demonstration of significant alterations in the hepatitis C virus (HCV) genome in nonresponsive or relapse patients infected with HCV-1 who were treated with interferon via the standard thrice-weekly regimen," Polyak et al. wrote ("Evolution of HCV Quasispecies in Hypervariable Region 1 and the Putative Interferon...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry